Contact

  • | Corporate, Regulated information

Mithra Releases Invitation to its General Shareholders’ Meeting

Liege, Belgium, 25 April 2023 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the invitation to its general shareholders’ meeting that will be held on Thursday May 25 2023 at 2:00 PM (CEST).

The notice for the General Meeting including a description of the formalities to participate in the meeting is available on the website investors.mithra.com.

 

Admission requirements

As referred in the meeting’s invitation published in the Belgian press, the right to participate in the general shareholder’s meeting and to vote is subject to the prior registration of the shares under the shareholder’s name on 11 May 2023 at midnight (CEST) (the “Record Date“), either by way of registration on the company’s share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.

A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.

The shareholder indicates his willingness to participate in the General Meeting by 19 May 2023 at the latest. This must be done by email to corporate.secretary@mithra.com, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.

 

Right to ask questions

The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address corporate.secretary@mithra.com or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on 19 May 2023 at the latest.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company’s website (www.mithra.com).

 

Proxies

Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.

Shareholders wishing to be represented must send the completed and signed proxy[1] form to the Company on 19 May 2023 at the latest, by email, fax or mail to Mithra’s headquarter.

Shareholders wishing to vote by mail must send the completed and signed proxy form[2] to the Company on 19 May 2023 at the latest, by email, fax or mail to Mithra’s headquarter.

Further information on the exercise of this right is available on the Company’s website (www.mithra.com). The proxy and voting forms may be obtained on the Company’s website (www.mithra.com) or upon request at the Company’s registered office, or by email to corporate.secretary@mithra.com.

Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.

 

Available documents

All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company’s website (www.mithra.com) as from 25 April 2023. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company’s registered office and/or, upon display of their securities, obtain copies of these documents free of charge.

Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to corporate.secretary@mithra.com.

 

_____

[1] The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended

[2] See (1)

 

Download press release

PDF version

Share it

Latest news

View all

Don't miss our news

Get the latest news: subscribe to our newsletter!

Subscribe
Go to Newsroom
Contact

Disclaimer

Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.

THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN ARE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.

Abort